CJC-1295 Without DAC Peptide: What It Is and How It Works

CJC-1295 without DAC peptide is a synthetic growth hormone-releasing hormone (GHRH) analog that signals the pituitary gland to produce more growth hormone, but it clears the bloodstream in roughly 30 minutes. Because it lacks the Drug Affinity Complex (DAC) that keeps the longer-acting version active for days, it creates short, pulse-like GH signals instead of a steady elevation. It is sold as a research chemical and is not approved by the FDA for human use.

What Is CJC-1295 Without DAC?

If you are asking what is cjc-1295 without dac, the simplest answer is that it is modified GRF(1-29) — a 29-amino-acid fragment of GHRH with four substitutions that make it resistant to the enzymes that normally break the hormone down. Researchers often call it Mod GRF 1-29, or simply the cjc-1295 no dac peptide.

The "without DAC" label refers to the missing maleimidopropionic acid group. That group attaches the peptide to albumin in the blood, which is what stretches the half-life from minutes to roughly 6–8 days. Remove it, and you get a compound that behaves much more like the body's natural GHRH rhythm.

CJC-1295 With DAC or Without: How the Two Versions Compare

The two forms share the same GHRH backbone, but the DAC changes almost everything about how they behave. When people weigh cjc-1295 with dac or without, they are usually choosing between dosing convenience and a more physiological release pattern.

Feature	CJC-1295 With DAC	CJC-1295 Without DAC
Half-life	About 6–8 days	About 30 minutes
GH release pattern	Continuous, elevated baseline	Short pulses that mimic natural rhythm
Typical research dosing	1–2 injections per week	2–3 injections per day
Albumin binding	Yes (via DAC)	No
Common research pairings	Often used alone for sustained exposure	Commonly stacked with ghrelin-mimetic peptides

How CJC-1295 Without DAC Works in the Body

The peptide binds GHRH receptors on somatotroph cells in the anterior pituitary. That binding raises cyclic AMP inside the cell, which triggers release of stored growth hormone into circulation. Because the peptide disappears quickly, each injection creates a discrete GH pulse rather than a flat, all-day elevation.

That difference matters to researchers studying pulsatility. Growth hormone is normally secreted in bursts, especially during deep sleep and after intense exercise. A short-acting GHRH analog fits that pattern more closely, which is why it is frequently combined with ghrelin-receptor agonists such as ipamorelin in laboratory protocols.

What About IGF-1?

Growth hormone released by the pituitary drives the liver to produce insulin-like growth factor 1 (IGF-1). With the DAC version, sustained GH exposure tends to raise IGF-1 more steadily. With the no-DAC version, IGF-1 changes are smaller and more transient, which some researchers view as a closer match to normal physiology.

CJC 1295 Without DAC Benefits Reported in Research

Most of what gets described as cjc 1295 without dac benefits comes from animal studies or anecdotal human reports, not from large controlled trials. Published animal work has looked at:

• Increased amplitude of natural growth hormone pulses
• Higher circulating IGF-1 after repeated administration
• Shifts in body composition markers, including lean mass and fat mass
• Faster recovery indicators in some injury models

Human data remain thin. No large randomized trial shows that CJC-1295 without DAC improves body composition, athletic performance, or recovery in healthy adults. The longer-lasting version has its own set of proposed cjc-1295 with dac peptide benefits, but it also carries the downside of continuous growth hormone exposure.

CJC 1295 Without DAC Dosage Per Week in Published Protocols

There is no FDA-approved human dose. Research protocols that circulate online typically use 100 mcg per injection, given two to three times daily. That works out to roughly 1,400–2,100 mcg per week, usually split into a morning dose and a pre-sleep dose.

Protocol	Per injection	Frequency	Approx. weekly total
Low	100 mcg	2x daily	1,400 mcg
Moderate	100 mcg	3x daily	2,100 mcg
Higher	200 mcg	2x daily	2,800 mcg

Those numbers are not clinical recommendations. When people search for cjc 1295 without dac dosage per week, the honest answer is that no regulatory body has established a safe or effective schedule for humans. Anyone considering use should speak with a licensed healthcare professional first.

Safety, Legality, and Buying Considerations

CJC-1295 without DAC is not FDA-approved for any human indication. In the United States it is sold as a research chemical, which means it is not regulated for purity, sterility, or dose accuracy the way prescription drugs are.

Reported side effects from user accounts include injection-site irritation, flushing, headache, water retention, and joint discomfort. Because the peptide raises growth hormone, long-term supraphysiologic exposure carries theoretical risks such as insulin resistance and tissue overgrowth, although these have not been well studied for this specific compound.

• Look for third-party certificates of analysis (COAs) before trusting any vendor.
• Be skeptical of products marketed with disease-treatment claims.
• Avoid combining research peptides with prescription medications without medical supervision.

The Bottom Line

CJC-1295 without DAC is a short-acting GHRH analog that produces brief, natural-looking growth hormone pulses rather than the week-long elevation seen with the DAC version. CJC-1295 is not FDA-approved for human use in the United States, and human efficacy data are limited. Anyone exploring GHRH-related research should consult a healthcare professional and rely on verified, third-party-tested material.

COMMON QUESTIONS

Frequently Asked Questions

What is the difference between CJC-1295 with DAC and without DAC?

The DAC group binds the peptide to albumin in the blood and extends its half-life to roughly 6–8 days, while CJC-1295 without DAC clears in about 30 minutes. That makes the DAC version suited to infrequent dosing and the no-DAC version suited to pulse-style research protocols. Both share the same GHRH backbone.

How often is CJC-1295 without DAC dosed in research protocols?

Most published and online protocols use 100 mcg two to three times daily, often in the morning and before sleep. That totals roughly 1,400–2,100 mcg per week. No regulatory agency has approved a human dose, so these figures are for research reference only.

Is CJC-1295 without DAC FDA-approved?

No. CJC-1295 without DAC is not FDA-approved for human use in the United States and is sold as a research chemical. Products marketed for human consumption sit outside FDA oversight, so purity and sterility are not guaranteed. Talk to a healthcare professional before considering any use.